When I look at my other biotech investments: acad, xoma, lxrx, ghdx (others)..., I have to say INO kind of looks cheap. I know it had a huge move, but in the scheme of things, when looking at the opportunity, I see no reason why this new would not warrant at least 2x from here. Now. However, any more good news, why not 10x. Still not a crazy market cap when you compare other speculative big opportunity biotechs. Thoughts?
I think it makes more sense to speculate the current market cap by looking at the individual assets. Here are some just off the top of my head.
1. Electroporation Technology
2. Cervical Cancer Treatment Vaccine
3. Prostate Cancer Vaccine
4. Hep C
5. HIV (Preventive & Therapeutic)
8. Influenza (Universal)
9. Influenza H7N9
12. Foot-And-Mouth Disease
14. Marburg Filovirus
16. Synthetic DNA Creation Technology
I believe that a large chunk of the $264m market cap can be accounted for by the electroporation technology alone. Throw on top of this that the company has zero debt, lots of third party funding & experienced management with recent insider buying.